The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Early Phase 1

Completed

Conditions: Childhood Diffuse Large Cell Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Adult Burkitt Lymphoma

Interventions: Drug: busulfan
Drug: etoposide
Drug: cyclophosphamide
Procedure: peripheral blood stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2013-10-10

Last Posted Date: 2015-08-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT01959477

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Phase 1

Terminated

Conditions: Stage II Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma
Stage I Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Drug: bortezomib
Drug: lenalidomide
Other: laboratory biomarker analysis

First Posted Date: 2013-10-07

Last Posted Date: 2017-02-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT01954784

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery

Phase 1

Withdrawn

Conditions: Stage IA Pancreatic Cancer
Stage IIB Pancreatic Cancer
Stage IB Pancreatic Cancer
Stage IIA Pancreatic Cancer

Interventions: Drug: metformin hydrochloride
Other: pharmacological study

First Posted Date: 2013-10-07

Last Posted Date: 2015-07-15

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01954732

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Phase 3

Completed

Conditions: Non-Hodgkin Lymphoma
Hodgkins Disease
Acute Biphenotypic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Lymphoblastic Leukemia
Multiple Myeloma

Interventions: Drug: tacrolimus
Drug: methotrexate
Drug: Mycophenolate mofetil
Drug: Methotrexate (low dose)

First Posted Date: 2013-09-27

Last Posted Date: 2023-09-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 101

Registration Number: NCT01951885

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Not Applicable

Terminated

Conditions: Stage I Endometrial Carcinoma
Stage II Endometrial Carcinoma
Stage III Endometrial Carcinoma
Stage IV Endometrial Carcinoma

Interventions: Procedure: lymph node mapping
Procedure: sentinel lymph node biopsy
Drug: isosulfan blue
Drug: indocyanine green solution
Procedure: therapeutic conventional surgery
Procedure: lymphadenectomy

First Posted Date: 2013-09-11

Last Posted Date: 2020-08-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT01939028

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Enzalutamide in Patients With High-risk Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate

Interventions: Drug: enzalutamide

First Posted Date: 2013-08-22

Last Posted Date: 2019-03-20

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT01927627

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Recurrent Adult Brain Tumor
Adult Gliosarcoma
Adult Glioblastoma

Interventions: Biological: Bevacizumab
Device: NovoTTF-l00A
Other: Quality of Life Assessment

First Posted Date: 2013-07-09

Last Posted Date: 2025-02-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01894061

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Diagnostic Test: positron emission tomography/computed tomography
Diagnostic Test: PET/MRI
Device: Position Device

First Posted Date: 2013-07-04

Last Posted Date: 2020-03-04

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 43

Registration Number: NCT01892540

Locations: 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

Phase 1

Recruiting

Conditions: Tumors Metastatic to Brain

Interventions: Radiation: radiosurgery
Procedure: therapeutic conventional surgery
Procedure: quality-of-life assessment

First Posted Date: 2013-07-03

Last Posted Date: 2024-12-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT01891318

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer

Not Applicable

Completed

Conditions: Advanced Breast Cancer
Stage 4 Breast Cancer
Recurrent Breast Cancer

Interventions: Other: Surveys
Other: T-PAT

First Posted Date: 2013-06-12

Last Posted Date: 2015-11-26

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 29

Registration Number: NCT01876238

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Home Terms & Conditions Privacy Policy